These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 22902168)
1. New concepts and best practices for management of pre- and post-transplantation cancer. Campistol JM; Cuervas-Mons V; Manito N; Almenar L; Arias M; Casafont F; Del Castillo D; Crespo-Leiro MG; Delgado JF; Herrero JI; Jara P; Morales JM; Navarro M; Oppenheimer F; Prieto M; Pulpón LA; Rimola A; Román A; Serón D; Ussetti P; Transplant Rev (Orlando); 2012 Oct; 26(4):261-79. PubMed ID: 22902168 [TBL] [Abstract][Full Text] [Related]
2. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology. Valantine H J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777 [TBL] [Abstract][Full Text] [Related]
3. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Gutierrez-Dalmau A; Campistol JM Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218 [TBL] [Abstract][Full Text] [Related]
4. Pre- and posttransplant management of solid organ transplant recipients: risk-adjusted follow-up. Shafaeddin Schreve B; Anliker M; Arnold AW; Kempf W; Laffitte E; Lapointe AK; Mainetti C; Pelloni F; Oberholzer P; Serra A; Streit M; Hofbauer GF; Curr Probl Dermatol; 2012; 43():57-70. PubMed ID: 22377920 [TBL] [Abstract][Full Text] [Related]
5. Fighting malignancy in organ transplant recipients. Geissler EK Transplant Proc; 2009; 41(6 Suppl):S9-12. PubMed ID: 19651298 [TBL] [Abstract][Full Text] [Related]
6. Management of de novo malignancies after liver transplantation. Pillai AA Transplant Rev (Orlando); 2015 Jan; 29(1):38-41. PubMed ID: 25510578 [TBL] [Abstract][Full Text] [Related]
8. Variability in immunization guidelines in children before and after lung transplantation. Benden C; Danziger-Isakov LA; Astor T; Aurora P; Bluemchen K; Boyer D; Conrad C; Eichler I; Elidemir O; Goldfarb S; Michaels MG; Mogayzel PJ; Mueller C; Parakininkas D; Oberkfell D; Solomon M; Boehler A Pediatr Transplant; 2007 Dec; 11(8):882-7. PubMed ID: 17976123 [TBL] [Abstract][Full Text] [Related]
9. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center. Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661 [TBL] [Abstract][Full Text] [Related]
10. Daunting but Worthy Goal: Reducing the De Novo Cancer Incidence After Transplantation. Dantal J; Campone M Transplantation; 2016 Dec; 100(12):2569-2583. PubMed ID: 27861286 [TBL] [Abstract][Full Text] [Related]
11. Burden of de novo malignancy in the liver transplant recipient. Chandok N; Watt KD Liver Transpl; 2012 Nov; 18(11):1277-89. PubMed ID: 22887956 [TBL] [Abstract][Full Text] [Related]
12. Report from the National Transplantation Pregnancy Registry: outcomes of pregnancy after transplantation. Armenti VT; Daller JA; Constantinescu S; Silva P; Radomski JS; Moritz MJ; Gaughan WJ; McGrory CH; Coscia LA Clin Transpl; 2006; ():57-70. PubMed ID: 18368705 [TBL] [Abstract][Full Text] [Related]
13. Post-transplant de novo malignancies in renal transplant recipients: the past and present. Kauffman HM; Cherikh WS; McBride MA; Cheng Y; Hanto DW Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677 [TBL] [Abstract][Full Text] [Related]
14. Low recurrence of preexisting extrahepatic malignancies after liver transplantation. Benten D; Sterneck M; Panse J; Rogiers X; Lohse AW Liver Transpl; 2008 Jun; 14(6):789-98. PubMed ID: 18412260 [TBL] [Abstract][Full Text] [Related]
15. [Swiss clinical practice guidelines for skin cancer in organ transplant recipients]. Lapointe AK; Hofbauer G; Anliker M; Arnold A; Binet I; Hunger R; Kempf W; Pascual M; Pelloni F; Serra A; Laffitte E Rev Med Suisse; 2010 Apr; 6(246):854-9. PubMed ID: 20455382 [TBL] [Abstract][Full Text] [Related]
17. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases. Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287 [TBL] [Abstract][Full Text] [Related]
18. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience. Ju MK; Joo DJ; Kim SJ; Huh KH; Kim MS; Jeon KO; Kim HJ; Kim SI; Kim YS Transpl Int; 2009 Jun; 22(6):644-53. PubMed ID: 19220824 [TBL] [Abstract][Full Text] [Related]
19. [Skin cancer in renal transplant recipients]. Mangino M; Schena FP G Ital Nefrol; 2010; 27 Suppl 50():S75-80. PubMed ID: 20922700 [TBL] [Abstract][Full Text] [Related]
20. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance. Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]